Holen Sie sich die Stockscreener-App
2.40
3.61%
-0.09
Handel nachbörslich:
2.36
-0.04
-1.67%
Schlusskurs vom Vortag:
$2.49
Offen:
$2.48
24-Stunden-Volumen:
346.65K
Relative Volume:
1.06
Marktkapitalisierung:
$39.01M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-64.47M
KGV:
-0.388
EPS:
-6.1852
Netto-Cashflow:
$-52.33M
1W Leistung:
-3.61%
1M Leistung:
-6.98%
6M Leistung:
-35.31%
1J Leistung:
-83.70%
1-Tages-Spanne:
$2.34
$2.5699
1-Wochen-Bereich:
$2.29
$2.5699
52-Wochen-Spanne:
$2.215
$26.05
Jasper Therapeutics Inc Stock (JSPR) Company Profile
Firmenname
Jasper Therapeutics Inc
Sektor
Branche
Telefon
(650) 549-1400
Adresse
2200 BRIDGE PKWY SUITE #102, REDWOOD CITY
Vergleichen Sie JSPR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
JSPR
Jasper Therapeutics Inc
|
2.40 | 69.53M | 0 | -64.47M | -52.33M | -6.1852 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Jasper Therapeutics Inc Stock (JSPR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-08 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2025-07-08 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-07-07 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-07-07 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-02-13 | Eingeleitet | UBS | Buy |
| 2024-12-06 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-09-09 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-07-08 | Eingeleitet | BTIG Research | Buy |
| 2024-06-27 | Eingeleitet | Stifel | Buy |
| 2024-05-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-04-03 | Eingeleitet | Evercore ISI | Outperform |
| 2024-03-28 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-03-18 | Eingeleitet | TD Cowen | Outperform |
| 2023-08-11 | Eingeleitet | CapitalOne | Overweight |
| 2022-02-28 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-11-08 | Eingeleitet | Credit Suisse | Outperform |
| 2021-10-21 | Eingeleitet | William Blair | Outperform |
| 2021-10-20 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-10-13 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Jasper Therapeutics Inc Aktie (JSPR) Neueste Nachrichten
JSPR INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper - GlobeNewswire
JSPR INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper - GlobeNewswire Inc.
Bragar Eagel & Squire, P.C. Reminds Investors of Jasper, KBR, Spirit Aviation, and Molina to Contact the Firm About their Rights in Filed Class Action Lawsuits - GlobeNewswire
Deadline Alert: Jasper Therapeutics, Inc. (JSPR) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit - GlobeNewswire
JSPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces That Jasper Therapeutics, Inc. Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit - FinancialContent
Portnoy Law Firm Announces Class Action on Behalf of Jasper Therapeutics, Inc. Investors - GlobeNewswire
JSPR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Jasper Therapeutics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
What analysts say about Jasper Therapeutics Inc Equity Warrant stockCup and Handle Formations & Rapid Capital Trading Tips - earlytimes.in
Pomerantz Law Firm Announces the Filing of a Class Action Against Jasper Therapeutics, Inc. and Certain OfficersJSPR - PR Newswire
DEADLINE ALERT for CYTK, NX, JSPR, and KBR: The Law Offices - GlobeNewswire
JSPR DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper - GlobeNewswire
Jasper Therapeutics, Inc. (JSPR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - Eastern Progress
JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit - Your Wyoming Link
Bragar Eagel & Squire, P.C. Reminds Investors of Jasper, - GlobeNewswire
Important Notice to Long-Term Shareholders of Humana Inc. - GlobeNewswire
Jasper Therapeutics, Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsJSPR - MarketScreener
Robbins LLP Reminds Jasper Therapeutics, Inc. Investors of the Upcoming Lead Plaintiff Deadline in the Class Action Against JSPR - Eastern Progress
JSPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
ROSEN, A GLOBAL INVESTOR RIGHTS LAW FIRM, Encourages Jasper - GlobeNewswire
Inside INdiana Business - FinancialContent
JSPR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Jasper Therapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper - MarketScreener
Jasper Therapeutics, Inc. (JSPR) Shareholders Who Lost Money Hav - GuruFocus
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Jasper - GlobeNewswire
JSPR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Jasper Therapeutics, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
About Us - FinancialContent
JASPER CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire
Deadline Alert: Jasper Therapeutics, Inc. (JSPR) - GlobeNewswire
Oklahoma City NewsThe Oklahoman - FinancialContent
Upcoming Events - FinancialContent
JSPR Stockholders With Large Losses Should Contact Robbins LLP For Information About The Jasper Therapeutics, Inc. Securities Fraud Class Action - ACCESS Newswire
JSPR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Jasper Therapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Deadline Approaching: Jasper Therapeutics, Inc. (JSPR) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith - MarketScreener
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Jasper Therapeutics, Inc. Investors to Secure - Bluefield Daily Telegraph
Press Telegram - FinancialContent
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Encourages Jasper Therapeutics, Inc. (JSPR) Shareholders To Inquire About Securities Fraud Class Action - MarketScreener
JSPR Bronstein, Gewirtz & Grossman LLC Announces that Jasper Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - MarketScreener
Faruqi & Faruqi Reminds Jasper Investors of the Pending - GlobeNewswire
Jasper Therapeutics CEO Martell buys $99,630 in shares By Investing.com - Investing.com Australia
JSPR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Jasper Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Jasper Therapeutics prices $30M equity offering - MSN
Finanzdaten der Jasper Therapeutics Inc-Aktie (JSPR)
Umsatz
Nettogewinn
Free Cashflow
ENV
Jasper Therapeutics Inc-Aktie (JSPR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Lucas Svetlana | Director |
Sep 22 '25 |
Buy |
2.43 |
20,000 |
48,600 |
20,000 |
| MARTELL RON | President and CEO |
Sep 22 '25 |
Buy |
2.43 |
41,000 |
99,630 |
74,118 |
| Shizuru Judith Anne | Director |
Sep 22 '25 |
Buy |
2.43 |
41,000 |
99,630 |
156,901 |
| Mahal Jeetinder Singh | Chief Operating Officer |
Dec 12 '24 |
Option Exercise |
7.10 |
900 |
6,390 |
25,909 |
| Mahal Jeetinder Singh | Chief Operating Officer |
Dec 12 '24 |
Sale |
22.11 |
900 |
19,899 |
25,009 |
5.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):